## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.4% in lower entry zone (4.0-10.0%), top quartile (89th pct) cross-sectional ranking. Short-term MRS_5 (1.9%) confirms momentum alignment. Strong momentum (+2.5% 5-day acceleration). Outperforming sector by 4.9%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($123.78)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Price-Driven Insight from (ZTS) for Rule-Based Strategy**
- Source: Stock Traders Daily | 20260104T040400 | Somewhat-Bearish | Relevance: 100%
- This article provides a price-driven insight into Zoetis Inc. Class A (NYSE: ZTS) for rule-based trading strategies. It highlights a mixed sentiment alignment indicating choppiness, an exceptional short setup, and divergent sentiment across horizons. The report also details three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss zones for different risk profiles.

**2. IDEXX Laboratories: How a Quiet Diagnostics Giant Is Rewriting the Future of Animal Health**
- Source: AD HOC NEWS | 20260104T060839 | Somewhat-Bullish | Relevance: 72%
- IDEXX Laboratories has transformed veterinary diagnostics into a high-margin, high-tech platform business by integrating in-clinic analyzers, reference lab services, software, and AI tools. This ecosystem approach provides a unified workflow for veterinary practices and addresses the rising demand for sophisticated animal healthcare amidst workforce shortages. The company's unique selling proposition lies in its data and AI capabilities, workflow integration, and recurring revenue model, contributing to its strong market valuation and competitive edge against rivals like Zoetis and Antech Diagnostics.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $136 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Volume divergence: price rising (+2.5% MRS) on declining volume (62% of avg) suggests distribution.
2. Long-term trend broken: trading 12.0% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +2.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.36 elevated, pricing in significant growth expectations. Forward P/E 19.1x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $57.3B |
| Beta | 0.97 |
| 52W Range | $115.25 - $177.40 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.36 |
| Forward P/E | 19.1 |
| Current P/E | 20.4 |
| YoY Growth | 7.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 2.9% to 5.4% (+2.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 at 1.9% confirms short-term momentum alignment. AM_20 at 5.6% shows strong absolute momentum above own 20MA. Outperforming sector by 4.9pp, stock-specific strength. Below SMA200 (0.88x), long-term trend not supportive. MACD histogram positive (1.00), confirming momentum. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.42% (CS: 89) | Strong |
| RSI_14 | 63.8 | Neutral |
| MACD Histogram | 1.00 | Bullish |
| vs SMA20 | 1.056x | Above |
| vs SMA50 | 1.028x | Above |
| vs SMA200 | 0.880x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $129.38
- **Stop Loss:** $123.78 (4.3% risk)
- **Target:** $137.78 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 154
- **Position Value:** $19,924.52
- **Portfolio %:** 19.92%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*